One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. / Svensson, C. K.; Larsen, J. R.; Vedtofte, L.; Jakobsen, M. S.L.; Jespersen, H. R.; Jakobsen, M. I.; Koyuncu, K.; Schjerning, O.; Nielsen, J.; Ekstrøm, C. T.; Correll, C. U.; Vilsbøll, T.; Fink-Jensen, A.
In: Acta Psychiatrica Scandinavica, Vol. 139, No. 1, 2019, p. 26-36.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients
AU - Svensson, C. K.
AU - Larsen, J. R.
AU - Vedtofte, L.
AU - Jakobsen, M. S.L.
AU - Jespersen, H. R.
AU - Jakobsen, M. I.
AU - Koyuncu, K.
AU - Schjerning, O.
AU - Nielsen, J.
AU - Ekstrøm, C. T.
AU - Correll, C. U.
AU - Vilsbøll, T.
AU - Fink-Jensen, A.
PY - 2019
Y1 - 2019
N2 - Objective: Treatment with most antipsychotics is associated with an increased risk of weight gain and metabolic disturbances. In a randomized trial, we previously demonstrated that 16 weeks of glucagon-like peptide-1 receptor agonist liraglutide treatment vs. placebo significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine. The aim of this study was to investigate whether the beneficial effects of the 16-week intervention were sustained beyond the intervention period. Method: One year after completion of the intervention, we investigated changes in body weight, fasting glucose, glycated hemoglobin, C-peptide, and lipids comparing 1-year follow-up levels to end of treatment (week 16) and baseline (week 0) levels. Results: From end of treatment to the 1-year follow-up, body weight had increased in the liraglutide-treated group. However, compared to baseline levels, the placebo-subtracted body weight loss remained significantly reduced (−3.8 kg, 95% CI: −7.3 to −0.2, P = 0.04). Fasting glucose, glycated hemoglobin, C-peptide, and lipids had each returned to baseline levels 1 year after stopping liraglutide. Conclusion: The body weight reduction during 16 weeks of liraglutide treatment was partially sustained 1 year after the intervention was completed. However, the improvements in other metabolic parameters returned to baseline levels.
AB - Objective: Treatment with most antipsychotics is associated with an increased risk of weight gain and metabolic disturbances. In a randomized trial, we previously demonstrated that 16 weeks of glucagon-like peptide-1 receptor agonist liraglutide treatment vs. placebo significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine. The aim of this study was to investigate whether the beneficial effects of the 16-week intervention were sustained beyond the intervention period. Method: One year after completion of the intervention, we investigated changes in body weight, fasting glucose, glycated hemoglobin, C-peptide, and lipids comparing 1-year follow-up levels to end of treatment (week 16) and baseline (week 0) levels. Results: From end of treatment to the 1-year follow-up, body weight had increased in the liraglutide-treated group. However, compared to baseline levels, the placebo-subtracted body weight loss remained significantly reduced (−3.8 kg, 95% CI: −7.3 to −0.2, P = 0.04). Fasting glucose, glycated hemoglobin, C-peptide, and lipids had each returned to baseline levels 1 year after stopping liraglutide. Conclusion: The body weight reduction during 16 weeks of liraglutide treatment was partially sustained 1 year after the intervention was completed. However, the improvements in other metabolic parameters returned to baseline levels.
KW - clozapine
KW - GLP-1
KW - liraglutide
KW - olanzapine
KW - overweight
KW - prediabetes
KW - schizophrenia
U2 - 10.1111/acps.12982
DO - 10.1111/acps.12982
M3 - Journal article
C2 - 30374965
AN - SCOPUS:85057534658
VL - 139
SP - 26
EP - 36
JO - Acta Psychiatrica Scandinavica
JF - Acta Psychiatrica Scandinavica
SN - 0001-690X
IS - 1
ER -
ID: 210293306